Skip to main content
. Author manuscript; available in PMC: 2021 Sep 17.
Published in final edited form as: Cancer Treat Res Commun. 2020 Sep 17;25:100210. doi: 10.1016/j.ctarc.2020.100210

Fig. 9. Mito-MGN inhibits melanoma tumor progression in vivo.

Fig. 9.

(A) Representative micro-CT images from UACC-62 xenografted (T - tumor) mice treated three times per week with vehicle (left) or 1 mg/tumor Mito-MGN (right). Data representative of four to six mice per group. (B) Quantification of tumor wet weight measured ex vivo on day 58. Values are mean ± SEM, n = 4–6, ** P ≤ 0.01 determined using an ANOVA with Tukey’s post hoc test.